-
Cue Biopharma NASDAQ:CUE Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the treatment of cancer, infectious diseases and autoimmune diseases. The company's proprietary platform, Immuno-STAT ™(Selective Targeting and Alteration of T cells) is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation.
Location: 21 Erie St, Massachusetts, 02139-4260, US | Website: www.cuebiopharma.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
41.79M
Cash
30.03M
Avg Qtr Burn
-9.633M
Short % of Float
3.69%
Insider Ownership
0.55%
Institutional Own.
23.60%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CUE-102 Details Wilms' Tumor 1 (WT1), Cancer | Phase 1 Update | |
CUE-101 (IL-2) +/- pembrolizumab Details Head and neck cancer, Head and neck squamous cell carcinoma, Cancer, Solid tumor/s, Human papillomavirus | Phase 1 Update |